Relypsa, Inc. is a clinical-stage pharmaceutical company leading the discovery and development of novel non-absorbed polymeric drugs for important applications in cardiovascular and renal diseases. Relypsa's lead product candidate is patiromer, a non-absorbed potassium binder for the treatment of hyperkalemia. Relypsa is pursuing the discovery of additional product candidates through use of its proprietary polymer platform.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 08/15/12 | $80,000,000 | Series C |
5AM Ventures Delphi Ventures New Leaf Venture Partners OrbiMed Advisors Sibling Capital | undisclosed |
